{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T02:29:56Z","timestamp":1789266596387,"version":"build-2803163510"},"reference-count":43,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2020,12,30]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Hypertension, one of the most common cardiovascular diseases that can\ncause coronary disease, stroke, myocardial infarction, and sudden death, it is the major contributor to\ncardiac failure as well as renal insufficiency.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>As there are many cardio-active pyridazinone-base derivatives in clinical use, therefore,\nwe aimed to synthesize a new series of pyridazin-3-ones and evaluate their vasorelaxant activity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title> Methods:<\/jats:title>\n<jats:p>A new series of synthesized compounds were carried out first by the synthesis of 6-\nflouroarylpyridazinones by cyclization of 3-(4-flourobenzoyl) propionic acid with hydrazine hydrate\nor arylhydrazines to provide the corresponding pyridazinone derivatives 2a-d. Mannich reaction was\nperformed using morpholine or piperidine formaldehyde to obtain compounds 3a,b. On the other\nhand, reaction of 2a with various chloroacetamide intermediates, in dimethylformamide and potassium\ncarbonate as a catalyst, afforded the target compounds 5a-c. The aromatic acid hydrazide intermediates\n6a-g were prepared in 50-90% yield, by reacting to the prepared esters with hydrazine\nhydrate under reflux in ethanol. The two compounds 8a,b were prepared via condensation of 7a,b\nwith ethyl chloroacetate in dry acetone. Finally, the target 2,4,6-trisubstituted pyridazinones 9a-c\nderivatives were obtained by the reaction of 7a with the appropriate aromatic aldehyde or substituted\nacetophenones. The new compounds were then evaluated for their vasorelaxant properties using\nisolated thoracic rat aortic rings. In addition, a homology model was built and molecular modeling\nsimulation of these compounds into the active sites of the newly created \u03b11a-adrenoceptor model was\nperformed in order to predict and rationalize their affinities toward this receptor.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Among these compounds; 5a was the most potent, it exhibited approximately two-times the\nactivity of prazosin (IC50 = 0.250, 0.487 mmol, respectively) also, fourteen compounds were more\npotent than prazosin.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573406416666200327191100","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T16:22:23Z","timestamp":1585326143000},"page":"171-186","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Synthesis, Molecular Modeling of Novel Substituted Pyridazinones and their Vasorelaxant Activities"],"prefix":"10.2174","volume":"17","author":[{"given":"Magda M.F.","family":"Ismail","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia H.S.","family":"Soliman","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona H. Abd","family":"Elmoniem","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gehad A.R. Abdel","family":"Jaleel","sequence":"additional","affiliation":[{"name":"Pharmacology Department, National Research Centre, Dokki, Giza 12622, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","author":"Oartes J.A.","unstructured":"Oartes J.A.;  Antihypertensive Agents and the Drug Therapy of HypertensionGoodman & Gilman\u2019s The Pharmacological Basis of Therapeutics 9th ed.; Pergamon Press, 2001, Vol. 780, Section V.33."},{"key":"ref=2","first-page":"1","volume":"193","author":"Kung H.C.","year":"2015","unstructured":"Kung H.C.; Xu, J. Hypertension-related Mortality in the United States, 2000\u20132013. NCHS 2015,193,1-8","journal-title":"NCHS"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1751-7176.2011.00512.x","volume":"13","author":"Sica D.A.","year":"2011","unstructured":"Sica D.A.; Carter B.; Cushman W.; Hamm L.; Thiazide and loop diuretics. J Clin Hypertens (Greenwich) 2011,13(9),639-643","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1093\/eurheartj\/ehr177","volume":"32","author":"Sever P.S.","year":"2011","unstructured":"Sever P.S.; Messerli F.H.; Hypertension management 2011: optimal combination therapy. Eur Heart J 2011,32(20),2499-2506","journal-title":"Eur Heart J"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ijcard.2014.11.031","volume":"177","author":"D\u00e9zsi C.A.","year":"2014","unstructured":"D\u00e9zsi C.A.; A review of clinical studies on angiotensin II receptor blockers and risk of cancer. Int J Cardiol 2014,177(3),748-753","journal-title":"Int J Cardiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1524-6175.2005.04140.x","volume":"8","author":"Sica D.A.","year":"2006","unstructured":"Sica D.A.; Pharmacotherapy review: calcium channel blockers. J Clin Hypertens (Greenwich) 2006,8(1),53-56","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/978-3-319-15961-4","author":"Jagadeesh G.","year":"2015","unstructured":"Jagadeesh G.;  Balakumar; Maung-U, PK Pathophysiology and Pharmacotherapy of Cardiovascular Disease 2015,853-868","journal-title":"Balakumar; Maung-U, PK Pathophysiology and Pharmacotherapy of Cardiovascular Disease"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11906-007-0050-2","volume":"9","author":"Pedersen M.E.","year":"2007","unstructured":"Pedersen M.E.; Cockcroft J.R.; The vasodilatory beta-blockers. Curr Hypertens Rep 2007,9(4),269-277","journal-title":"Curr Hypertens Rep"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/clc.4960131104","volume":"13","author":"Nash D.T.","year":"1990","unstructured":"Nash D.T.; Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism. Clin Cardiol 1990,13(11),764-772","journal-title":"Clin Cardiol"},{"key":"ref=10","first-page":"403","volume":"298","author":"Piascik M.T.","year":"2001","unstructured":"Piascik M.T.; Perez D.M.; \u03b11-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther 2001,298(2),403-410","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s12272-013-0095-5","volume":"36","author":"Khalil N.A.","year":"2013","unstructured":"Khalil N.A.; Ahmed E.M.; Elshihawy H.A.; Zaitone S.A.; Novel 4-substituted-2(1H)-phthalazinone derivatives: synthesis, molecular modeling study and their effects on \u03b1-receptors. Arch Pharm Res 2013,36(6),671-683","journal-title":"Arch Pharm Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/qshc.5.2.111","volume":"5","author":"Melville A.","year":"1996","unstructured":"Melville A.; Donovon J.; Sheldon T.; Peters T.; Benign prostatic hyperplasia. Qual Health Care 1996,5(2),111-119","journal-title":"Qual Health Care"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/j.1476-5381.1996.tb15480.x","volume":"118","author":"Kenny B.A.","year":"1996","unstructured":"Kenny B.A.; Miller A.M.; Williamson I.J.R.; O\u2019Connell J.; Chalmers D.H.; Naylor A.M.; Evaluation of the pharmacological selectivity profile of \u03b1 1 adrenoceptor antagonists at prostatic \u03b1 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol 1996,118(4),871-878","journal-title":"Br J Pharmacol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/S0022-5347(17)39751-3","volume":"144","author":"Lepor H.","year":"1990","unstructured":"Lepor H.; Knapp-Maloney G.; Sunshine H.; A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1990,144(6),1393-1397","journal-title":"J Urol"},{"key":"ref=15","first-page":"2","volume":"2","author":"Akhmola V.","year":"2018","unstructured":"Akhmola V.; Jawla S.; Mishra R.; Synthesis, characterization and antihypertensive activity of 4,5 dihydropyridazin-3(2h)-one derivatives. Acta Scientific Pharmaceutical Sc 2018,2(5),2-7","journal-title":"Acta Scientific Pharmaceutical Sc"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.bmc.2007.09.031","volume":"16","author":"Abouzid K.","year":"2008","unstructured":"Abouzid K.; Abdel Hakeem M.; Khalil O.; Maklad Y.; Pyridazinone derivatives: design, synthesis, and in vitro vasorelaxant activity. Bioorg Med Chem 2008,16(1),382-389","journal-title":"Bioorg Med Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ddr.21079","volume":"74","author":"Bansal R.","year":"2013","unstructured":"Bansal R.; Kumar D.; Sharma D.; Calle C.; Carron R.; Synthesis and pharmacological evaluation of 6\u2010arylpyridazinones as potent vasorelaxants. Drug Dev Res 2013,74(5),296-305","journal-title":"Drug Dev Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/S0968-0896(02)00146-3","volume":"10","author":"Sotelo E.","year":"2002","unstructured":"Sotelo E.; Fraiz N.; Y\u00e1\u00f1ez M.; Terrades V.; Laguna R.; Cano E.; Ravi\u00f1a E.; Pyridazines. Part XXIX: synthesis and platelet aggregation inhibition activity of 5-substituted-6-phenyl-3(2H)-pyridazinones. Novel aspects of their biological actions. Bioorg Med Chem 2002,10(9),2873-2882","journal-title":"Bioorg Med Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12272-010-2222-x","volume":"33","author":"Amin E.N.","year":"2010","unstructured":"Amin E.N.; Abdel-Alim A.A.M.; Abdel-Moty S.G.; El-Shorbagi A.N.; Abdel-Rahman M.Sh.; Synthesis of new 4,5-3(2H)pyridazinone derivatives and their cardiotonic, hypotensive, and platelet aggregation inhibition activities. Arch Pharm Res 2010,33(1),25-46","journal-title":"Arch Pharm Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1016\/j.ejmech.2009.06.006","volume":"44","author":"Bansal R.","year":"2009","unstructured":"Bansal R.; Kumar D.; Carron R.; de la Calle C.; Synthesis and vasodilatory activity of some amide derivatives of 6-(4-carboxymethyloxyphenyl)-4,5-dihydro-3(2H)-pyridazinone. Eur J Med Chem 2009,44(11),4441-4447","journal-title":"Eur J Med Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1016\/j.ejmech.2010.02.003","volume":"45","author":"Siddiqui A.A.","year":"2010","unstructured":"Siddiqui A.A.; Mishra R.; Shaharyar M.; Synthesis, characterization and antihypertensive activity of pyridazinone derivatives. Eur J Med Chem 2010,45(6),2283-2290","journal-title":"Eur J Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1527-3466.1990.tb00399.x","volume":"8","author":"Barrett J.A.","year":"1990","unstructured":"Barrett J.A.; Meacham, R. H.; Kelley, M. F.; Graney, W. F.; Perrone, M. H. Prinoxodan (RG W-2938). Cardiovasc Drug Rev 1990,8,323-338","journal-title":"Cardiovasc Drug Rev"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/BF00166968","volume":"342","author":"Galvan M.","year":"1990","unstructured":"Galvan M.; Schudt C.; Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle. Naunyn Schmiedebergs Arch Pharmacol 1990,342(2),221-227","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1213\/01.ane.0000244326.38206.a0","volume":"103","author":"Montes F.R.","year":"2006","unstructured":"Montes F.R.; Echeverri D.; Buitrago L.; Ram\u00edrez I.; Giraldo J.C.; Maldonado J.D.; Uma\u00f1a J.P.; The vasodilatory effects of levosimendan on the human internal mammary artery. Anesth Analg 2006,103(5),1094-1098","journal-title":"Anesth Analg"},{"key":"ref=25","first-page":"227","volume":"5","author":"Nieminen M.S.","year":"2013","unstructured":"Nieminen M.S.; Fruhwald S.; Heunks L.M.A.; Suominen P.K.; Gordon A.C.; Kivikko M.; Pollesello P.; Levosimendan: current data, clinical use and future development. Heart Lung Vessel 2013,5(4),227-245","journal-title":"Heart Lung Vessel"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/eurheartj\/ehi875","volume":"27","author":"De Luca L.","year":"2006","unstructured":"De Luca L.; Colucci W.S.; Nieminen M.S.; Massie B.M.; Gheorghiade M.; Evidence-based use of levosimendan in different clinical settings. Eur Heart J 2006,27(16),1908-1920","journal-title":"Eur Heart J"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0968-0896(94)00144-R","volume":"3","author":"Roark W.H.","year":"1995","unstructured":"Roark W.H.; Padia J.; Bolton G.L.; Blankley C.J.; Essenburg A.D.; Stanfield R.L.; Bousley R.F.; Krause B.R.; Roth B.D.; Bioisosterism in drug design: identification of and structure-activity relationships in a series of glycine anilide ACAT inhibitors. Bioorg Med Chem 1995,3(1),29-39","journal-title":"Bioorg Med Chem"},{"key":"ref=28","first-page":"590","volume":"2","author":"Adeoye I.O.","year":"2007","unstructured":"Adeoye I.O.; Adelowo O.O.; Oladipo M.A.; Odunola O.A.; Comparison of bactericidal and fungicidal activities of Cu (Ii) and Ni (Ii) complexes of para-methoxy and para-hydroxy benzoic acid hydrazide. Research. J Appl Sci (Faisalabad) 2007,2,590-594","journal-title":"J Appl Sci (Faisalabad)"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ejmech.2013.03.066","volume":"64","author":"Giovannoni M.P.","year":"2013","unstructured":"Giovannoni M.P.; Schepetkin I.A.; Cilibrizzi A.; Crocetti L.; Khlebnikov A.I.; Dahlgren C.; Graziano A.; Dal Piaz V.; Kirpotina L.N.; Zerbinati S.; Vergelli C.; Quinn M.T.; Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists. Eur J Med Chem 2013,64,512-528","journal-title":"Eur J Med Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejmech.2012.02.051","volume":"52","author":"Awadallah F.M.","year":"2012","unstructured":"Awadallah F.M.; el-Eraky W.I.; Saleh D.O.; Synthesis, vasorelaxant activity, and molecular modeling study of some new phthalazine derivatives. Eur J Med Chem 2012,52,14-21","journal-title":"Eur J Med Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1016\/j.febslet.2014.10.033","volume":"588","author":"Ma\u00efga A.","year":"2014","unstructured":"Ma\u00efga A.; Dupont M.; Blanchet G.; Marcon E.; Gilquin B.; Servent D.; Gilles N.; Molecular exploration of the \u03b1(1A)-adrenoceptor orthosteric site: binding site definition for epinephrine, HEAT and prazosin. FEBS Lett 2014,588(24),4613-4619","journal-title":"FEBS Lett"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0068841","volume":"8","author":"Ma\u0131ga A.","year":"2013","unstructured":"Ma\u0131ga A.; Merlin J.; Marcon E.; Rouget C.; Larregola M.; Gilquin B.; Fruchart-Gaillard C.; Lajeunesse E.; Marchetti C.; Lorphelin A.; Bellanger L.; Summers R.J.; Hutchinson D.S.; Evans B.A.; Servent D.; Gilles N.; Orthosteric Binding of \u03c1-Da1a, a Natural Peptide of Snake Venom Interacting Selectively with the \u03b11A-Adrenoceptor. PLoS One 2013,8,1-11","journal-title":"PLoS One"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.bmcl.2010.12.028","volume":"21","author":"Siddiqui A.A.","year":"2011","unstructured":"Siddiqui A.A.; Mishra R.; Shaharyar M.; Husain A.; Rashid M.; Pal P.; Triazole incorporated pyridazinones as a new class of antihypertensive agents: design, synthesis and in vivo screening. Bioorg Med Chem Lett 2011,21(3),1023-1026","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1016\/j.ejmech.2010.05.050","volume":"45","author":"Ismail M.M.F.","year":"2010","unstructured":"Ismail M.M.F.; Rateb H.S.; Hussein M.M.M.; Synthesis and docking studies of novel benzopyran-2-ones with anticancer activity. Eur J Med Chem 2010,45(9),3950-3959","journal-title":"Eur J Med Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3906\/kim-1706-51","volume":"42","author":"Bayindir S.","year":"2018","unstructured":"Bayindir S.; Ayna Adnan, Temel Y., CiFTCi, M. The synthesis of new oxindoles as analogs of natural product 3,3\u2032-bis(indolyl)oxindole and in vitro evaluation for enzyme activity of G6PD and 6PGD. Turk J Chem 2018,42,332-345","journal-title":"Turk J Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"22193","DOI":"10.1002\/jbt.22193","volume":"32","author":"Bayindir S.","year":"2018","unstructured":"Bayindir S.; Temel Y.A.; Adnan; CiFTCi, M. The synthesis of N-benzoylindoles as inhibitors of G6PD and 6PGD. J Biochem Mol Toxicol 2018,32(9),22193","journal-title":"J Biochem Mol Toxicol"},{"key":"ref=37","doi-asserted-by":"publisher","unstructured":"Bayindir, S.; Caglayan, C.; Karaman, M.; G\u00fclcin, \u0130. The green synthesis and molecular docking of novel N-substituted rhodanines as effective inhibitors for carbonic anhydrase and acetylcholinesterase enzymes. Bioorg. Chem., 2019, 90, 103096.","DOI":"10.1016\/j.bioorg.2019.103096"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ejmech.2014.05.052","volume":"82","author":"Mun\u00edn J.","year":"2014","unstructured":"Mun\u00edn J.; Quezada E.; Cui\u00f1as A.; Campos-Toimil M.; Uriarte E.; Santana L.; Vi\u00f1a D.; Synthesis, biological evaluation and structure-activity relationships of new phthalazinedione derivatives with vasorelaxant activity. Eur J Med Chem 2014,82,407-417","journal-title":"Eur J Med Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.1016\/j.bmcl.2010.09.031","volume":"20","author":"Costas T.","year":"2010","unstructured":"Costas T.; Besada P.; Piras A.; Acevedo L.; Ya\u00f1ez M.; Orallo F.; Laguna R.; Ter\u00e1n C.; New pyridazinone derivatives with vasorelaxant and platelet antiaggregatory activities. Bioorg Med Chem Lett 2010,20(22),6624-6627","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1107\/S0021889892009944","volume":"26","author":"Laskowski R.A.","year":"1993","unstructured":"Laskowski R.A.; MacArthur M.W.; Moss D.S.; Thornton J.M.; PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 1993,26,283-291","journal-title":"J Appl Cryst"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/prot.340120407","volume":"12","author":"Morris A.L.","year":"1992","unstructured":"Morris A.L.; MacArthur M.W.; Hutchinson E.G.; Thornton J.M.; Stereochemical quality of protein structure coordinates. Proteins 1992,12(4),345-364","journal-title":"Proteins"},{"key":"ref=42","author":"Piechota P.","year":"2015","unstructured":"Piechota P.;  Development of in silico models for the prediction of toxicity incorporating ADME information 2015","journal-title":"Development of in silico models for the prediction of toxicity incorporating ADME information"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"Daina A.","year":"2017","unstructured":"Daina A.; Michielin O.; Zoete V.; SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017,7,42717","journal-title":"Sci Rep"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/180549","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/180549\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/180549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T15:25:12Z","timestamp":1638804312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/180549\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,30]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,12,30]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573406416666200327191100","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,30]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}